

DOI: [10.4081/ejh.2020.3122](https://doi.org/10.4081/ejh.2020.3122)

### Galunisertib enhances chimeric antigen receptor-modified T cell function

Zhixiong Wang,<sup>1,2,3</sup> Qian Liu,<sup>1</sup> Na Risu,<sup>3</sup> Jiayu Fu,<sup>3</sup> Yan Zou,<sup>4</sup> Jiaxing Tang,<sup>4</sup> Long Li,<sup>4</sup>  
Hui Liu,<sup>1</sup> Guomin Zhou,<sup>1</sup> Xuekai Zhu<sup>4</sup>

<sup>1</sup>School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, China

<sup>2</sup>Ma'anshan University, Ma'anshan, China


<sup>3</sup>Division of Health Science, Graduate School of Medicine, Osaka University, Osaka, Japan

<sup>4</sup>Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University, Shanghai, China

**Correspondence:** Xuekai Zhu, Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University, 393 Middle Huaxia Road, Pudong, Shanghai 201210, China. Tel. +86.021.20685207. Email: zhuxk@shanghaitech.edu.cn


**Key words:** CAR T; TGF- $\beta$ ; solid tumor; immunotherapy; immunosuppression.

---



### Supplementary Figure 1.

Galunisertib does not affect the antigen expression on tumor cells. U251 CD133-OE luc or MDA-MB-453 luc was treated with Gal, DMSO or culture medium (D-10) for two days. Cells were stained with antibodies against CD133 or HER2, and then detected by flow cytometry.



**Supplementary Figure 2.**

Galunisertib has no significant effect on the expression of CD69 on CAR T.